Chong Kun Dang Pharmaceutical Corp.
Chong Kun Dang Pharmaceutical Corp.
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cardioprotective Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Korean Patients With Type 2 Diabetes | Diabetes Complications, Diabetic Cardiomyopathies, Nutritional and Metabolic Diseases, cardiomyopathy, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Not stated | 2026-08-18 | NCT07770737 | |
| SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study | Nutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, heart failure, metabolic disease, type 2 diabetes mellitus | Active, not recruiting | Not stated | 2025-09-30 | NCT07198191 | |
| A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH) | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Not applicable | 2025-04-24 | NCT06627322 | |
| Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 | 2025-03-06 | NCT05704621 |